pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Tecvayli
drug
save

teclistamab

Marketedupdated 3mo ago
by Janssen Biotech Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugTECVAYLI44 co-mentions · 11 sources
  • tagApproval44 co-mentions · 11 sources
  • companyJanssen Biotech Inc22 co-mentions · 11 sources

all catalysts(11)

approval · 11
Oct 25, 2022
approval
4y ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Aug 9, 2023
approval
3y ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Nov 16, 2023
approval
3y ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Feb 20, 2024
approval
2y ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
May 28, 2024
approval
2y ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Jul 2, 2024
approval
2y ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Nov 22, 2024
approval
2y ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Dec 2, 2024
approval
2y ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Aug 19, 2025
approval
12mo ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Oct 2, 2025
approval
11mo ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Mar 5, 2026
approval
5mo ago
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
view all 11 catalysts →

Trials studying teclistamab

  • phase1A Study of Teclistamab and Mezigdomide in People With Multiple Myelomarecruitingn=18
  • phase2A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).recruitingn=30
  • phase3A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomideactive not recruitingn=838
  • phase3A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myelomanot yet recruitingn=520
  • phase3A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myelomarecruitingn=400
  • phase1A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myelomaactive not recruitingn=140
  • phase2A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myelomacompletedn=40
  • phase2A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myelomaactive not recruitingn=43
more trials →

News(6)

  • Legend Biotech CEO abruptly steps down without permanent replacement
    In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
    fiercebiotech · 19d ago
  • Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
    Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
    biopharma_dive · 21d ago
  • ‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
    A string of recent wins on the frontiers of novel drug development could mean that a homegrown innovation industry is within reach.
    fiercebiotech · 29d ago
  • On second try, Acadia drug gets nod from European regulators
    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
    biopharma_dive · 1mo ago
  • CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
    A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
    biopharma_dive · 3mo ago
  • FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
    Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…
    biopharma_dive · 3mo ago
brand
Tecvayli
generic
teclistamab-cqyv
indication
Refractory Multiple Myeloma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 25m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?